期刊文献+

降钙素原在细菌性肺炎及肺结核中的鉴别研究 被引量:29

Value research of procalcitonin in the identification between bacterial pneumonia and pulmonary tuberculosis
下载PDF
导出
摘要 目的通过测定细菌性肺炎及肺结核患者血清降钙素原水平进一步探讨降钙素原对这两种疾病的鉴别诊断价值。方法收集细菌性肺炎患者(20例)及肺结核患者(21例)血清标本,两组患者病情严重程度达到系统性炎症反应综合征(SIRS)水平,采用免疫荧光法分别检测两组患者血清降钙素原水平,并进行比较,绘制ROC曲线,根据曲线下面积评价降钙素原对上述两种疾病的鉴别诊断价值。结果细菌性肺炎患者血清降钙素原水平明显高于肺结核患者(P<0.05),绘制ROC曲线后,曲线下面积(AUC)为0.923,95%可信区间为(0.844,1.000),在临界值为0.20 ng/ml时,其灵敏度为85%,特异度为86%。结论降钙素原在临界值为0.20 ng/ml时,对达到SIRS水平的细菌性肺炎及肺结核患者具有良好的鉴别诊断价值。 Objective To explore the differential value of procalcitonin between bacterial pneumonia and pulmonary tuberculosis.Methods The serum procalcitonin of patients with bacterial pneumonia(20 cases) and pulmonary tuberculosis(21 cases) was detected by immunofluorescence and then compared.All patients were suffering from systemic inflammatory response syndrome(SIRS).ROC curves were described and the differential value of procalcitonin was evaluated according to AUC.Results The level of serum procalcitonin was significantly higher in patients with bacterial pneumonia than in patients with pulmonary tuberculosis(P0.05).The AUC of ROC curve was 0.923,95%CI(0.844,1.000).At the cut-off value of 0.20 ng/ml,the sensitivity was 85%,and the specificity was 86%.Conclusion When the level of procalcitonin reaches the cut-off value of 0.20 ng/ml,procalcitonin can be used as a valuable clinical inflammatory marker to differentiate bacterial pneumonia and pulmonary tuberculosis with SIRS.
出处 《临床肺科杂志》 2013年第5期786-788,共3页 Journal of Clinical Pulmonary Medicine
关键词 降钙素原 肺炎 肺结核 系统性炎症反应综合征 procalcitonin pneumonia pulmonary tuberculosis systemic inflammatory response syndrome
  • 相关文献

参考文献10

  • 1Lippi G, Meschi T, Cervellin G. Inflammatory biomarkers for the diagnosis, monitoring and follow-up of community-acquired pneu- monia: Clinical evidence and perspectives[J]. European Journal of Internal Medicine. 2011. 22 ( 5 ) :460 - 465.
  • 2肺结核诊断和治疗指南[J].中华结核和呼吸杂志,2001,24(2):70-74. 被引量:2863
  • 3社区获得性肺炎诊断和治疗指南[J].中华结核和呼吸杂志,2006,29(10):651-655. 被引量:3052
  • 4Bone RC, Balk RA, Cerra FB, et al. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference : definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis[J]. Crit Care Med, 1992,20(6) : 864 - 874.
  • 5Kang YA, Kwon SY, Yoon HI, et al. Role of C-Reactive Proteinand Procalcitonin in Differentiation of Tuberculosis from Bacterial Community Acquired Pneumonia [ J ]. Korean J Intern Med, 2009, 24(4) : 337 -342.
  • 6Naderi M, Hashemi M, Kouhpayeh H, et al. The status of serum procalcitonin in pulmonary tuberculosis and nontuberculosis pulmo- nary disease[J]. J Pak Med Assoc, 2009, 59(9) :647 -648.
  • 7Gilbert DN. Procalcitonin as a Biomarker in Respiratory Tract Infec- tion[J]. Clin Infect Dis, 2011, 52 Suppl 4:$346 -50.
  • 8Standage SW, Wong HR. Biomarkers for pediatric sepsis and septic shock[ J ]. Expert Rev Anti Infect Ther, 2011, 9 (1) :71 -79.
  • 9Cozmei C, Constantinescu D, Carasevici E,et al. Thl and Th2 cyto- kine response in patients with pulmonary tuberculosis and health care workers occupationally exposed to M. tuberculosis [ J ]. Rev Med Chir Soc Med Nat Iasi, 2007,111 (3) :702 - 709.
  • 10Wang JH. The application of ROC curve in clinical diagnostic exper- iment[ J ]. Chinese Journal of Hypertension, 2008,16 ( 2 ) : 175 - 177.

二级参考文献24

  • 1沈定霞,罗燕萍,崔岩,赵莉萍,白立彦.分离产金属β-内酰胺酶的铜绿假单胞菌[J].中华医院感染学杂志,2004,14(1):86-88. 被引量:109
  • 2刘又宁,陈民钧,赵铁梅,王辉,王睿,刘庆锋,蔡柏蔷,曹彬,孙铁英,胡云建,修清玉,周新,丁星,杨岚,卓建生,唐英春,张扣兴,梁德荣,吕晓菊,李胜歧,刘勇,俞云松,魏泽庆,应可净,赵峰,陈萍,侯晓娜.中国城市成人社区获得性肺炎665例病原学多中心调查[J].中华结核和呼吸杂志,2006,29(1):3-8. 被引量:788
  • 3Ngeow YF,Suwanjutha S,Chantarojanasriri T,et al.An Asian study on the prevalence of atypical respiratory pathogens in community-acquired pneumonia.Int J Infect Dis,2005,9:144-153.
  • 4de Roux A,Marcos MA,Garcia E,et al.Viral community-acquired pneumonia in nonimmunocompromised adults.Chest,2004,125:1343-1351.
  • 5Ostrosky-Zeichner L,Alexander BD,Kett DH,et al.Multicenter clinical evaluation of the (1→3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans.Clin Infect Dis,2005,41:654-659.
  • 6Food and Drug Administration,HHS.Class Ⅱ Special Controls Guidance Document:serological assays for the detection of betaglucan.Fed Reqist,2004,69:56934-56936.
  • 7Mandell LA,Marrie TJ,Grossman RF,et al.Canadian guidelines for the initial management of community-acquired pneumonia:an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society.The Canadian CommunityAcquired Pneumonia Working Group.Clin Infect Dis,2000,31:383-421.
  • 8Woodhead M,Blasi F,Ewig S,et al.Guidelines for the management of adult lower respiratory tract infections.Eur Respir J,2005,26:1138-1180.
  • 9Mandell LA,Bartlett JG,Dowell SF,et al.Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults.Clin Infect Dis,2003,37:1405-1433.
  • 10Fine MJ,Auble TE,Yealy DM,et al.A prediction rule to identify low risk patients with community-acquired pneumonia.N Engl J Med,1997,336:243-250.

共引文献5895

同被引文献232

引证文献29

二级引证文献201

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部